Clinical Trial

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 2, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-09.
Trial Details
NCT Number NCT06591793
Lead Sponsor AAVantgarde Bio Srl
Conditions Usher Syndrome, Type 1B
Enrollment 15 participants
Start Date 2024-07-02
Primary Completion 2025-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2025-05-02